	US 12,076,461 B2
	Use of resected liver serum for whole liver-engineering
Jeffrey Ross, Chaska, MN (US); Anne Young, New Brighton, MN (US); Allie Haarstad, Bloomington, MN (US); and Scott Nyberg, Rochester, MN (US)
Assigned to Miromatrix Medical Inc., Eden Prairie, MN (US); and Mayo Foundation for Medical Education & Research, Mayo Medical Ventures, Rochester, MN (US)
Filed by Miromatrix Medical Inc., Eden Prairie, MN (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Feb. 7, 2022, as Appl. No. 17/665,955.
Application 17/665,955 is a continuation of application No. 15/697,078, filed on Sep. 6, 2017, granted, now 11,278,643.
Claims priority of provisional application 62/383,772, filed on Sep. 6, 2016.
Prior Publication US 2022/0323645 A1, Oct. 13, 2022
Int. Cl. A61L 27/36 (2006.01); A61L 27/24 (2006.01); A61L 27/38 (2006.01); C12N 5/071 (2010.01)

CPC A61L 27/3616 (2013.01) [A61L 27/24 (2013.01); A61L 27/3604 (2013.01); A61L 27/3633 (2013.01); A61L 27/3683 (2013.01); A61L 27/3804 (2013.01); A61L 27/3808 (2013.01); A61L 27/3834 (2013.01); A61L 27/3839 (2013.01); C12N 5/0671 (2013.01); A61L 2430/28 (2013.01); C12N 2500/84 (2013.01); C12N 2533/90 (2013.01)]

13 Claims

1. A method comprising contacting a substrate with:

1) a plurality of cells comprising at least one hundred million primary hepatocytes, and

2) an aqueous composition comprising 2% to 3% of blood or serum isolated from a mammal subjected to a liver resection, wherein the substrate comprises an at least partially decellularized isolated extracellular matrix of a liver or a portion thereof.